491 related articles for article (PubMed ID: 14613284)
1. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group.
Costedoat-Chalumeau N; Amoura Z; Duhaut P; Huong DL; Sebbough D; Wechsler B; Vauthier D; Denjoy I; Lupoglazoff JM; Piette JC
Arthritis Rheum; 2003 Nov; 48(11):3207-11. PubMed ID: 14613284
[TBL] [Abstract][Full Text] [Related]
2. Hydroxychloroquine in lupus pregnancy.
Clowse ME; Magder L; Witter F; Petri M
Arthritis Rheum; 2006 Nov; 54(11):3640-7. PubMed ID: 17075810
[TBL] [Abstract][Full Text] [Related]
3. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature.
Costedoat-Chalumeau N; Amoura Z; Huong DL; Lechat P; Piette JC
Autoimmun Rev; 2005 Feb; 4(2):111-5. PubMed ID: 15722258
[TBL] [Abstract][Full Text] [Related]
4. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus.
Parke A; West B
J Rheumatol; 1996 Oct; 23(10):1715-8. PubMed ID: 8895146
[TBL] [Abstract][Full Text] [Related]
5. Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases.
Costedoat-Chalumeau N; Hulot JS; Amoura Z; Leroux G; Lechat P; Funck-Brentano C; Piette JC
Rheumatology (Oxford); 2007 May; 46(5):808-10. PubMed ID: 17202178
[TBL] [Abstract][Full Text] [Related]
6. Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group.
Costedoat-Chalumeau N; Amoura Z; Lupoglazoff JM; Huong DL; Denjoy I; Vauthier D; Sebbouh D; Fain O; Georgin-Lavialle S; Ghillani P; Musset L; Wechsler B; Duhaut P; Piette JC
Arthritis Rheum; 2004 Oct; 50(10):3187-94. PubMed ID: 15476223
[TBL] [Abstract][Full Text] [Related]
7. Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study.
Diav-Citrin O; Blyakhman S; Shechtman S; Ornoy A
Reprod Toxicol; 2013 Aug; 39():58-62. PubMed ID: 23602891
[TBL] [Abstract][Full Text] [Related]
8. Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy.
Abarientos C; Sperber K; Shapiro DL; Aronow WS; Chao CP; Ash JY
Expert Opin Drug Saf; 2011 Sep; 10(5):705-14. PubMed ID: 21417950
[TBL] [Abstract][Full Text] [Related]
9. [The safety of hydroxychloroquine in pregnant patients with systemic lupus erythematosus].
Zhang L; Ma L; Lin B; Wu DH; Wang GC
Zhonghua Nei Ke Za Zhi; 2011 Nov; 50(11):918-21. PubMed ID: 22333122
[TBL] [Abstract][Full Text] [Related]
10. Pregnancy outcome post renal transplantation.
Sgro MD; Barozzino T; Mirghani HM; Sermer M; Moscato L; Akoury H; Koren G; Chitayat DA
Teratology; 2002 Jan; 65(1):5-9. PubMed ID: 11835226
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM
J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
[TBL] [Abstract][Full Text] [Related]
12. Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus.
Koh JH; Ko HS; Kwok SK; Ju JH; Park SH
Lupus; 2015 Feb; 24(2):210-7. PubMed ID: 25305214
[TBL] [Abstract][Full Text] [Related]
13. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases.
Buchanan NM; Toubi E; Khamashta MA; Lima F; Kerslake S; Hughes GR
Ann Rheum Dis; 1996 Jul; 55(7):486-8. PubMed ID: 8774170
[TBL] [Abstract][Full Text] [Related]
14. Hydroxychloroquine prophylaxis for preeclampsia, hypertension and prematurity in pregnant patients with systemic lupus erythematosus: A meta-analysis.
Duan J; Ma D; Wen X; Guo Q; Gao J; Zhang G; Xu K; Zhang L
Lupus; 2021 Jun; 30(7):1163-1174. PubMed ID: 33853420
[TBL] [Abstract][Full Text] [Related]
15. Antimalarial drugs in pregnancy--the North American experience.
Parke AL; Rothfield NF
Lupus; 1996 Jun; 5 Suppl 1():S67-9. PubMed ID: 8803915
[TBL] [Abstract][Full Text] [Related]
16. Hydroxychloroquine for the prevention of fetal growth restriction and prematurity in lupus pregnancy: A systematic review and meta-analysis.
Guillotin V; Bouhet A; Barnetche T; Richez C; Truchetet ME; Seneschal J; Duffau P; Lazaro E;
Joint Bone Spine; 2018 Dec; 85(6):663-668. PubMed ID: 29631068
[TBL] [Abstract][Full Text] [Related]
17. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus.
Costedoat-Chalumeau N; Amoura Z; Hulot JS; Aymard G; Leroux G; Marra D; Lechat P; Piette JC
Ann Rheum Dis; 2007 Jun; 66(6):821-4. PubMed ID: 17324970
[TBL] [Abstract][Full Text] [Related]
18. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study.
Leroux M; Desveaux C; Parcevaux M; Julliac B; Gouyon JB; Dallay D; Pellegrin JL; Boukerrou M; Blanco P; Lazaro E
Lupus; 2015 Nov; 24(13):1384-91. PubMed ID: 26082465
[TBL] [Abstract][Full Text] [Related]
19. Pregnancy outcome following first trimester exposure to chloroquine.
Levy M; Buskila D; Gladman DD; Urowitz MB; Koren G
Am J Perinatol; 1991 May; 8(3):174-8. PubMed ID: 2029276
[TBL] [Abstract][Full Text] [Related]
20. Treatment of substance abuse during pregnancy and infant outcome.
Little BB; Snell LM; Van Beveren TT; Crowell RB; Trayler S; Johnston WL
Am J Perinatol; 2003 Jul; 20(5):255-62. PubMed ID: 13680509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]